HC Wainwright & Co. Initiates Coverage On Arcus Biosciences with Neutral Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Arcus Biosciences with a Neutral rating and set a price target of $20.
October 21, 2024 | 10:47 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has initiated coverage on Arcus Biosciences with a Neutral rating and a price target of $20, indicating a balanced view on the stock's potential.
The Neutral rating suggests that the analyst sees no strong reason for the stock to move significantly in either direction in the short term. The price target of $20 provides a benchmark for investors, but the neutral stance indicates a balanced view on the stock's potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100